loading
Schlusskurs vom Vortag:
$1.95
Offen:
$1.95
24-Stunden-Volumen:
2.13M
Relative Volume:
0.30
Marktkapitalisierung:
$404.86M
Einnahmen:
$176.23M
Nettoeinkommen (Verlust:
$-257.83M
KGV:
-1.3552
EPS:
-1.45
Netto-Cashflow:
$-246.00M
1W Leistung:
-8.75%
1M Leistung:
+114.88%
6M Leistung:
+228.41%
1J Leistung:
+424.85%
1-Tages-Spanne:
Value
$1.89
$2.03
1-Wochen-Bereich:
Value
$1.82
$2.185
52-Wochen-Spanne:
Value
$0.304
$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name
Firmenname
Sangamo Therapeutics Inc
Name
Telefon
(510) 970-6000
Name
Adresse
501 CANAL BLVD., RICHMOND, CA
Name
Mitarbeiter
405
Name
Twitter
@sangamotx
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
SGMO's Discussions on Twitter

Vergleichen Sie SGMO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
SGMO 1.96 404.86M 176.23M -257.83M -246.00M -1.45
VRTX 450.00 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.66 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 588.46 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 248.13 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.50 24.89B 3.30B -501.07M 1.03B 11.54

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-04-28 Herabstufung BofA Securities Neutral → Underperform
2023-02-27 Hochstufung Wedbush Neutral → Outperform
2023-01-06 Herabstufung BofA Securities Buy → Neutral
2022-06-13 Fortgesetzt Wedbush Neutral
2021-05-04 Eingeleitet RBC Capital Mkts Outperform
2021-01-07 Fortgesetzt Guggenheim Neutral
2021-01-06 Eingeleitet Stifel Hold
2020-12-16 Fortgesetzt H.C. Wainwright Buy
2020-09-08 Eingeleitet BofA Securities Buy
2020-07-07 Eingeleitet SunTrust Buy
2019-08-26 Eingeleitet H.C. Wainwright Buy
2018-11-14 Herabstufung JP Morgan Overweight → Neutral
2018-11-09 Herabstufung Guggenheim Buy → Neutral
2018-10-10 Eingeleitet Guggenheim Buy
2018-06-20 Eingeleitet BofA/Merrill Buy
2017-11-15 Hochstufung Piper Jaffray Neutral → Overweight
2017-06-22 Fortgesetzt Jefferies Buy
2016-11-01 Herabstufung Wedbush Outperform → Neutral
2016-10-19 Herabstufung Piper Jaffray Overweight → Neutral
2015-12-04 Eingeleitet Wells Fargo Outperform
2015-10-23 Fortgesetzt Jefferies Buy
2013-05-03 Eingeleitet BioLogic Equity Research Sell
2011-02-23 Bestätigt JMP Securities Mkt Outperform
2010-07-29 Bestätigt Wedbush Outperform
2009-10-19 Eingeleitet Brean Murray Sell
2009-10-07 Bestätigt Leerink Swann Outperform
2009-08-25 Bestätigt JMP Securities Mkt Outperform
Alle ansehen

Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten

pulisher
Nov 20, 2024

Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts - Simply Wall St

Nov 20, 2024
pulisher
Nov 19, 2024

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain - BioSpace

Nov 19, 2024
pulisher
Nov 19, 2024

Sangamo stock climbs 12% post-market on FDA update for ST-503 - MSN

Nov 19, 2024
pulisher
Nov 19, 2024

Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment - Marketscreener.com

Nov 19, 2024
pulisher
Nov 19, 2024

Sangamo's Novel Gene Therapy for Chronic Pain Gets FDA Clearance for Clinical Trials | SGMO Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 18, 2024

What is HC Wainwright's Forecast for SGMO FY2024 Earnings? - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

FY2028 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 15, 2024
pulisher
Nov 14, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $9.00 at Barclays - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces challenges, opportunities - Investing.com Canada

Nov 14, 2024
pulisher
Nov 13, 2024

Sangamo: Q3 Earnings Snapshot - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates - MSN

Nov 13, 2024
pulisher
Nov 13, 2024

Earnings call: Sangamo Therapeutics reports progress in gene therapies By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 13, 2024

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024
pulisher
Nov 13, 2024

Earnings call: Sangamo Therapeutics reports progress in gene therapies - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

SGMOSangamo Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Nov 13, 2024
pulisher
Nov 12, 2024

Sangamo Therapeutics Q3 beats propel stock 5% higher - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Sangamo Therapeutics earnings beat by $0.06, revenue topped estimates - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

Sangamo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results - Business Wire

Nov 12, 2024
pulisher
Nov 11, 2024

Sangamo Therapeutics's Earnings Outlook - Benzinga

Nov 11, 2024
pulisher
Nov 08, 2024

FY2024 Earnings Forecast for SGMO Issued By HC Wainwright - Defense World

Nov 08, 2024
pulisher
Nov 08, 2024

Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve

Nov 08, 2024
pulisher
Nov 07, 2024

Equities Analysts Set Expectations for SGMO FY2024 Earnings - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Reaches New 12-Month High on Analyst Upgrade - Defense World

Nov 07, 2024
pulisher
Nov 06, 2024

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - GlobeNewswire Inc.

Nov 06, 2024
pulisher
Nov 06, 2024

Sangamo (SGMO) Stock Rally Continues In Pre-Market Ahead of Financial Results Release - Stocks Telegraph

Nov 06, 2024
pulisher
Nov 05, 2024

Sangamo Therapeutics (SGMO) Set to Announce Quarterly Earnings on Tuesday - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $10.00 at HC Wainwright - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Reduction in Sangamo Therapeutics Inc - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - StockTitan

Nov 04, 2024
pulisher
Nov 01, 2024

individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World

Nov 01, 2024
pulisher
Nov 01, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat

Nov 01, 2024
pulisher
Oct 29, 2024

Gene Therapy Market Detailed Analysis and Forecast to 2031 - InsightAce Analytic

Oct 29, 2024
pulisher
Oct 26, 2024

StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate - Genetic Engineering & Biotechnology News

Oct 26, 2024
pulisher
Oct 25, 2024

Fabry disease gene therapy study data enough for FDA submission - Fabry Disease News

Oct 25, 2024
pulisher
Oct 25, 2024

Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News

Oct 25, 2024
pulisher
Oct 25, 2024

Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On FridayBooz Allen Hamilton (NYSE:BAH) - Benzinga

Oct 25, 2024
pulisher
Oct 24, 2024

Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads By Investing.com - Investing.com UK

Oct 24, 2024
pulisher
Oct 23, 2024

4 Analysts Have This To Say About Sangamo Therapeutics - Benzinga

Oct 23, 2024
pulisher
Oct 23, 2024

What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St

Oct 23, 2024
pulisher
Oct 23, 2024

Sangamo shares jump as FDA clears faster gene therapy pathway - The Pharma Letter

Oct 23, 2024
pulisher
Oct 22, 2024

Sangamo stock rallies 37% on FDA update for Fabry disease drug - MSN

Oct 22, 2024
pulisher
Oct 22, 2024

Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart

Oct 22, 2024
pulisher
Oct 22, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Traders Purchase Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat

Oct 22, 2024

Finanzdaten der Sangamo Therapeutics Inc-Aktie (SGMO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):